[Review Request] Intradermal Plant EVs as a Lymphatic "Trojan Horse": Turning Washout into Targeted Metastasis & Viral Reservoir Therapy

Joshua Dungan, inventor of PathMap.org, is requesting scientific review of an AI-assisted research run proposing that intradermal injection of small plant-derived extracellular vesicles (such as Ginger-EVs or Ginseng-EVs) could exploit size-dependent interstitial drainage to intentionally target regional lymph nodes, delivering therapeutic payloads to treat lymphatic metastases and viral reservoirs. The hypothesis includes using pH-responsive or enzyme-cleavable 'hitchhiker' peptides for triggered release in the lymphatic pre-metastatic niche, and ferroptosis induction in pre-metastatic niche macrophages via plant-EV delivery to prevent nodal metastatic colonization. Dungan also suggests that 6-shogaol from Ginger-EVs may block Ebola VP40 budding, potentially offering a therapeutic approach for viral aggregation pathologies.

TLDR; I am looking for scientific review of an AI-assisted research run I did today: PathMap.org link → I realized this morning that the parenthetical comment I made may warrant its own PathMap run and wow, I am excited to share this result For example, A hydrogel intradermal injection to deliver a therapeutic to a skin cancer lesion, or say, toenail fungus below the keratonized nailbed, likely cannot practically use ginger EVs or ginseng or other small exosome sized EVs because the lymphatic system can easily flush them away delivering off target to clearance instead of the intended target which could be a hack to deliver to clearance systems by the way, using small evs knowing they will “flush” So I tinkered around and formulated a hypothesis: “Intradermal administration of small plant-derived extracellular vesicles such as Ginger-EVs or Ginseng-EVs may exploit size-dependent interstitial drainage to intentionally target regional lymph nodes, thereby delivering therapeutic payloads directly to immune clearance systems to treat lymphatic metastases and viral reservoirs.” I was certain that my hypothesis is more like a discovery at least for me so I let the AI come up with a follow-query. It chose: “The conjugation of plant-derived nanovesicles with pH-responsive or enzyme-cleavable ‘hitchhiker’ peptides enables triggered release within the lymphatic pre-metastatic niche, thereby enhancing the therapeutic payload concentration specifically at sites of active lymphangiogenesis in patients with early-stage lymphatic metastasis.” The Swanson’s-style discovery adds a synergistic element regarding PDEVs: Discovered Hypothesis A to C : Ferroptosis induction in pre-metastatic niche macrophages via plant-EV delivery can prevent nodal metastatic colonization. If I understand this correctly, this may have major implications for treating / In my mind, the PDEVs delivery via intradermal delivery as described may also mean that non-chemotherapy therapeutics may become more feasible? For example, in the Ovarian Tumor research I mentioned in the other post describes how Ginger-EVs can/do contain 6-shogaol which is known to cause apoptosis in ovarian tumor cells, making it potentially a preferred EV for delivery if it were moxa/borneal-modified and delivered by injection in a thermogel . Further, since 6-shogaol also may block effective Ebola VP40 budding, is this potentially another hack to viral aggregation pathologies such as Ebola via intradermal hydrogel delivery? In the case of Ebola, the Ginger 6-shogaol EVs would have therapeutic benefits themselves, and given the ability to mod them with molecules and/or pack them otherwise, should this be investigated further? I would appreciate it if actual scientists reviewed this work, especially the idea of using the lymphatic flushing of PDEVs - not as a roadblock to a therapeutic pathway you had hoped to build for some other pathology - but for what it is, a potential gateway directly to a localized area of the lymph system for therapeutic delivery as its own target. Joshua Dungan inventor of PathMap.org http://PathMap.org